[Pathophysiologic rationales for clinical management of heart failure].
Sasayama
S
S
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D004734:Energy Metabolism; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D009200:Myocardial Contraction; D014665:Vasodilator Agents / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D014665:Vasodilator Agents